Sign in
Taking people in United StatesPhase 1/2

Spironolactone versus placebo for stiff aorta in thoracic aortic aneurysm

Tests whether spironolactone lowers aortic stiffness in people with thoracic aortic aneurysm.

Key facts

Who runs it
Mayo Clinic
Where
Rochester, United StatesSee the site
Trial code
Registry title
HEART: Pilot Randomized Controlled Trial
Status
Recruiting
Phase
Phase 1/2
People taking part
50 people, planned
Started
25 May 2026
Expected to end
May 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Spironolactone
  • Placebo
Record updated
8 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with a degenerative thoracic aortic aneurysm (a widening of the main artery in the chest). It tests whether spironolactone makes the aorta less stiff compared with placebo.

Age
18 years and older
Sex
All sexes
Disease stage
Degenerative aneurysm of the aortic root and/or ascending aorta, larger than normal for age, sex and body size (for example ≥ 4.0 cm (1.6 in)).
Earlier treatment
No blood pressure medicine, or the same blood pressure medicines for at least 4 weeks. People who have had aortic surgery or repair cannot join. People now taking spironolactone, eplerenone or finererone cannot join.
Biomarker or test result
Kidney function eGFR ≥ 50 mL/min/1.73 m². Blood potassium ≤ 5.1 mmol/L.

Main reasons for not taking part

  • Inherited aorta diseases such as Marfan, Loeys-Dietz, vascular Ehlers-Danlos or Turner syndrome, or a family or genetic form
  • Bicuspid aortic valve or inflammation of the aorta
  • Past aortic surgery, stent repair or acute aortic syndrome
  • Permanent atrial fibrillation or flutter, or major artery disease that blocks the stiffness measurement
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Adults ≥ 18 years old with dTAA of the aortic root and/or ascending aorta exceeding the upper limit of normal for age, sex, and body surface area (≥ 4.0 cm as an example of a common threshold; but age, sex and body size-specific thresholds have been established for the aortic root24 and ascending aorta25)
  • no antihypertensive use or stable antihypertensive regimen ≥ 4 weeks
  • eGFR ≥ 50 mL/min/1.73 m²
  • serum potassium ≤ 5.1 mmol/L
  • ability to provide informed consent

Who cannot take part

  • prior aortic surgery, endovascular repair, or acute aortic syndrome
  • Heritable aortopathies (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndromes; familial TAA, genetically-proven TAA)
  • major peripheral artery disease affecting the carotids, iliacs and/or external femoral arteries precluding cfPWV measurement
  • bicuspid aortic valve
  • inflammatory aortitis,
  • permanent atrial fibrillation/flutter
  • current use of spironolactone, eplerenone or finererone
  • pregnancy or lactation

Where in United States

  • Mayo Clinic in RochesterRochester, United StatesContact: Saad OmarTaking people

About the trial

What the trial wants to find out

The purpose of this study is to determine whether spironolactone reduces aortic stiffness, measured by carotid-femoral pulse wave velocity (cfPWV), compared with placebo, in patients with degenerative thoracic aortic aneurysms.

The 2 groups in the trial

  • SpironolactoneTreatment being tested
  • PlaceboPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Hemodynamic Effects Of Aldosterone Receptor Blockade In Degenerative Thoracic Aortic Aneurysm: A Pilot Randomized Controlled Trial (HEART: Pilot RCT)
Plain-language title
Spironolactone versus placebo for stiff aorta in thoracic aortic aneurysmGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
8 June 2026